Collegium Pharmaceutical (COLL) EBIT Margin (2016 - 2026)

Collegium Pharmaceutical's EBIT Margin history runs 11 years deep, the most recent figure standing at 15.97% for Q1 2026.

• On a quarterly basis, EBIT Margin rose 376.0% year-over-year to 15.97% in Q1 2026; TTM through Mar 2026 was 23.71%, a 364.0% decrease from a year earlier, with the FY2025 full-year figure at 23.01%, down 389.0% from the prior year.
• EBIT Margin slipped to 15.97% in Q1 2026 per COLL's latest filing, from 29.57% in the prior quarter.
• Across five years, EBIT Margin topped out at 102.34% in Q4 2024 and bottomed at 11.96% in Q1 2022.
• The 5-year median for EBIT Margin is 21.87% (2024), against an average of 25.65%.
• Across the five-year window, EBIT Margin soared 9738 bps in 2022 and tumbled 7277 bps in 2025, its largest moves.
• Year by year, EBIT Margin stood at 8.36% in 2022, then jumped by 393 bps to 41.2% in 2023, then surged by 148 bps to 102.34% in 2024, then sank by 71 bps to 29.57% in 2025, then plunged by 46 bps to 15.97% in 2026.
• Per Business Quant, the three latest COLL EBIT Margin figures stand at 15.97% (Q1 2026), 29.57% (Q4 2025), and 29.66% (Q3 2025).